ENLIVEN THERAPEUTICS INC (ELVN) Stock Price, Forecast & Analysis
NASDAQ:ELVN • US29337E1029
ELVN Key Statistics, Chart & Performance
The current stock price of ELVN is 26.72 USD. In the past month the price increased by 6.16%. In the past year, price increased by 23.25%.
ELVN Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ELVN. When comparing the yearly performance of all stocks, ELVN is one of the better performing stocks in the market, outperforming 81.29% of all stocks.
ELVN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ELVN. No worries on liquidiy or solvency for ELVN as it has an excellent financial health rating, but there are worries on the profitability.
ELVN Financial Highlights
Over the last trailing twelve months ELVN reported a non-GAAP Earnings per Share(EPS) of -1.84. The EPS increased by 3.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -19.8% | ||
| ROE | -20.42% | ||
| Debt/Equity | 0 |
ELVN Forecast & Estimates
16 analysts have analysed ELVN and the average price target is 41.59 USD. This implies a price increase of 55.66% is expected in the next year compared to the current price of 26.72.
ELVN Ownership
ELVN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.99 | 983.195B | ||
| JNJ | JOHNSON & JOHNSON | 20.9 | 586.544B | ||
| MRK | MERCK & CO. INC. | 22.44 | 301.342B | ||
| PFE | PFIZER INC | 9.18 | 156.812B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.98 | 123.651B | ||
| ZTS | ZOETIS INC | 18.44 | 55.813B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.71 | 26.086B | ||
| VTRS | VIATRIS INC | 6.23 | 18.163B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.04 | 12.486B | ||
| AXSM | AXSOME THERAPEUTICS INC | 221.27 | 9.135B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ELVN
Company Profile
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. The company is headquartered in Boulder, Colorado and currently employs 65 full-time employees. The company went IPO on 2020-03-12. The company is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. Its second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations. ELVN-002 is designed to inhibit wild type HER2 and key mutations of HER2, while sparing wild-type EGFR and avoiding EGFR-related toxicities.
Company Info
ENLIVEN THERAPEUTICS INC
6200 Lookout Road
Boulder COLORADO US
Employees: 62
Phone: 17206478519
ENLIVEN THERAPEUTICS INC / ELVN FAQ
What does ELVN do?
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. The company is headquartered in Boulder, Colorado and currently employs 65 full-time employees. The company went IPO on 2020-03-12. The company is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. Its second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations. ELVN-002 is designed to inhibit wild type HER2 and key mutations of HER2, while sparing wild-type EGFR and avoiding EGFR-related toxicities.
What is the stock price of ENLIVEN THERAPEUTICS INC today?
The current stock price of ELVN is 26.72 USD. The price decreased by -1.62% in the last trading session.
Does ENLIVEN THERAPEUTICS INC pay dividends?
ELVN does not pay a dividend.
What is the ChartMill rating of ENLIVEN THERAPEUTICS INC stock?
ELVN has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the market cap for ENLIVEN THERAPEUTICS INC?
ENLIVEN THERAPEUTICS INC (ELVN) has a market capitalization of 1.59B USD. This makes ELVN a Small Cap stock.
Can you provide the ownership details for ELVN stock?
You can find the ownership structure of ENLIVEN THERAPEUTICS INC (ELVN) on the Ownership tab.